scholarly journals Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206)

2017 ◽  
Vol 31 ◽  
pp. 31-43 ◽  
Author(s):  
J.H. Alfonso ◽  
A. Bauer ◽  
L. Bensefa-Colas ◽  
A. Boman ◽  
M. Bubas ◽  
...  
Keyword(s):  
Skin Diseases ◽  
Position Paper ◽  
Diagnosis And Treatment ◽  
Cost Action ◽  
Work Related ◽  
Minimum Standards ◽  
The Cost

Emerging issues and questions on peripartum depression prevention, diagnosis and treatment: a consensus report from the cost action riseup-PPD

2020 ◽  
Vol 274 ◽  
pp. 167-173 ◽  
Author(s):  
Ana Fonseca ◽  
Ana Ganho-Ávila ◽  
Mijke Lambregtse-van den Berg ◽  
Angela Lupattelli ◽  
Maria de la Fé Rodriguez-Muñoz ◽  
...  
Keyword(s):  
Diagnosis And Treatment ◽  
Depression Prevention ◽  
Cost Action ◽  
Emerging Issues ◽  
Peripartum Depression ◽  
The Cost ◽  
Consensus Report

scholarly journals Peptide hormone analysis in diagnosis and treatment of Differences of Sex Development: joint position paper of EU COST Action ‘DSDnet’ and European Reference Network on Rare Endocrine Conditions

2020 ◽  
Vol 182 (6) ◽  
pp. P1-P15
Author(s):  
T H Johannsen ◽  
A-M Andersson ◽  
S F Ahmed ◽  
Y B de Rijke ◽  
R F Greaves ◽  
...  
Keyword(s):  
Peptide Hormone ◽  
Position Paper ◽  
Inhibin B ◽  
Diagnosis And Treatment ◽  
Reference Network ◽  
Cost Action ◽  
Sex Development ◽  
European Reference Network ◽  
Differences Of Sex Development ◽  
Hormone Analysis

Differences of Sex Development (DSD) comprise a variety of congenital conditions characterized by atypical chromosomal, gonadal, or anatomical sex. Diagnosis and monitoring of treatment of patients suspected of DSD conditions include clinical examination, measurement of peptide and steroid hormones, and genetic analysis. This position paper on peptide hormone analyses in the diagnosis and control of patients with DSD was jointly prepared by specialists in the field of DSD and/or peptide hormone analysis from the European Cooperation in Science and Technology (COST) Action DSDnet (BM1303) and the European Reference Network on rare Endocrine Conditions (Endo-ERN). The goal of this position paper on peptide hormone analysis was to establish laboratory guidelines that may contribute to improve optimal diagnosis and treatment control of DSD. The essential peptide hormones used in the management of patients with DSD conditions are follicle-stimulating hormone, luteinising hormone, anti-Müllerian hormone, and Inhibin B. In this context, the following position statements have been proposed: serum and plasma are the preferred matrices; the peptide hormones can all be measured by immunoassay, while use of LC-MS/MS technology has yet to be implemented in a diagnostic setting; sex- and age-related reference values are mandatory in the evaluation of these hormones; and except for Inhibin B, external quality assurance programs are widely available.

scholarly journals GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 493
Author(s):  
Riccardo Di Fiore ◽  
Sherif Suleiman ◽  
Bridget Ellul ◽  
Sharon A. O’Toole ◽  
Charles Savona-Ventura ◽  
...  
Keyword(s):  
Cancer Research ◽  
Gynecological Cancer ◽  
Gynecologic Cancer ◽  
Delayed Diagnosis ◽  
Research Programme ◽  
Basic Research ◽  
Diagnosis And Treatment ◽  
Rare Cancer ◽  
Cost Action ◽  
Gynecologic Tumors

More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often based on expert opinion, retrospective studies, or extrapolation from other tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117 (European Network for Gynecological Rare Cancer Research) programme aims to address these challenges through the creation of a unique network between key stakeholders covering distinct domains from concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials. On this basis, members of this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological Cancer”) have decided to focus their future efforts on the development of new approaches to improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current state-of-the-art and describe the goals of this COST Action and its future challenges with the aim to stimulate discussion and promote synergy across scientists engaged in the fight against this rare cancer worldwide.

scholarly journals A novel theranostic activity-based probe targeting kallikrein 7 for diagnosis and treatment of skin diseases

2021 ◽  
Author(s):  
Evangelos Bisyris ◽  
Eleni Zingkou ◽  
Golfo G Kordopati ◽  
Minos-Timotheos Matsoukas ◽  
Plato A. Magriotis ◽  
...  
Keyword(s):  
In Silico ◽  
Skin Diseases ◽  
Diagnosis And Treatment ◽  
Protease Substrate

We applied a new in silico approach for fishing protease-substrate motifs to design a kallirein 7 (KLK7)-specific phosphonate activity-based probe (ABP) to quantify the active KLK7 in situ. Epidermal application...

HYGIENIC INFLUENCE OF PRODUCTION FACTORS ON THE EPIDEMIOLOGY OF DERMATOSES IN RAILWAY TRANSPORT WORKERS IN THE CONTEXT OF THE COVID-19 PANDEMIC

2021 ◽  
Author(s):  
O.A. Karpova ◽  
◽  
V.A. Semenikhin ◽  
B.A. Balandovich ◽  
◽  
...  
Keyword(s):  
Skin Diseases ◽  
Working Environment ◽  
Labor Process ◽  
Diagnosis And Treatment ◽  
Railway Transport ◽  
Working Population ◽  
Study Objective ◽  
Factors Affecting ◽  
Production Factors ◽  
Transport Workers

Abstract: Introduction. In the context of the COVID-19 pandemic, it is necessary to look for new approaches to the prevention, diagnosis and treatment of skin diseases in the working population. Study objective. To study the hygienic influence of harmful and dangerous factors of the working environment and the severity of the labor process on the structure of the general dermatological morbidity in railway transport workers who ensure the safety of train traffic in the conditions of the COVID-19 pandemic. Materials and methods. The complex of harmful production factors affecting railway transport workers was studied according to the sanitary and hygienic characteristics of the working conditions of employees of the Altai region of the West Siberian Railway of JSC "Russian Railways". The structure of the general dermatological morbidity was studied according to the statistical coupons of outpatient patients who applied to a dermatovenerologist in the CHUZ " CB "Russian Railways-Medicine" Barnaul for the period 2019-2020. Results. The conducted complex of hygienic, epidemiological and statistical studies showed that the combined impact of chemical, meteorological, physical, biological harmful production factors and the severity of the labor process (class 3.1-3.5) in railway transport workers who ensure the safety of train traffic leads to the development of such production-related skin diseases as contact dermatitis and psoriasis. In the context of the COVID-19 pandemic, skin infections (62.8%) predominate over non-infectious dermatoses in the structure of the total dermatological morbidity. The share of primary morbidity increased to 90.8%. The first rank is occupied by pyoderma (47.5%), the second – allergodermatoses (20.0%), the third – mycoses (11.6%). Conclusion. The COVID-19 pandemic leads to changes in the epidemiological and clinical features of dermatoses in the working population, which must be taken into account in their prevention, diagnosis and treatment.

Quality control plan for road bridges – overview of COST Action TU1406 WG3 final report

2019 ◽  
Author(s):  
Matej Kušar ◽  
Poul Linneberg ◽  
Joao Amado ◽  
Snežana Mašović ◽  
Nikola Tanasić ◽  
...  
Keyword(s):  
Quality Control ◽  
Failure Modes ◽  
Final Report ◽  
Control Plan ◽  
Cost Action ◽  
Working Groups ◽  
Group 3 ◽  
Arch Bridges ◽  
The Cost ◽  
Damage Processes

<p>The main objective of the COST Action TU1406 is to develop a guideline for the establishment of Quality Control plans for roadway bridges. The guideline is based on conclusions of Working groups 1 and 2 of the Action and is further developed with the contributions and findings of members of Working group 3. The paper presents the overview of the developed framework, where gradual damage processes as well as sudden events are being addressed in evaluation of Key Performance Indicators. The proposed framework relies on data from design and construction phase, as well as from results from visual inspections that are used for an assessment of safety and serviceability - the primary concerns of bridge managers. Special attention is aimed at possible Failure modes and related bridge Vulnerable zones. These are, for instance high moment regions, high shear regions and constructions joints, but can also be zones of bridge conceptual weaknesses. Since there are differences in design and materials for various bridge types, the suitability of the framework is tested separately for girder/frame bridges and arch bridges. Due to the specifics of sudden events, the application of the framework is given separately from gradual damage processes. Emphasis is given on flooding and scour as these are the most common culprits of bridge failures. The steps in the implementation of the framework are briefly shown and an illustrative example is presented.</p>

Sign in / Sign up

Export Citation Format

Share Document